Advanced Proton Therapy System is Available in Cancer Centers in Japan
Varian Medical Systems (NYSE: VAR) today announced it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam® system for proton therapy in Japan. This approval is the latest example of the growing worldwide interest in proton therapy as an advanced treatment option for cancer patients. Varian will be showcasing the ProBeam system at the Particle Therapy Co-Operative Group (PTCOG), May 11-13, 2017 in Yokohama, Japan.
Varian’s ProBeam system is the first to offer fully-integrated intensity modulated proton therapy (IMPT) to enable more efficient adaptive proton therapy. Varian’s pencil beam scanning technology gives clinicians the ability to deliver the dose precisely in the tumor to minimize dose to healthy tissue. When combined with cone beam computed tomography (CBCT), the ProBeam system enables advanced image-guided adaptive therapy during the course of treatment helping to make it the most precise form of proton therapy available.
With proton therapy, the risk of damage to healthy tissues and potential side effects are reduced because proton beams can be controlled so that they deposit their energy within the tumor site rather than passing all the way through the patient. The treatment is particularly suitable for pediatric cancer cases as well as for adults.
Moataz Karmalawy, general manager of Varian’s Particle Therapy division highlights, “We are very pleased that the ProBeam system has now received Shonin approval.” “This approval is an important step in the growing availability of proton therapy in Japan and around the world,” concluded Mr. Karmalawy.